Diabetes:1型干扰素通过STAT4-和颗粒酶B依赖性途径强化CD8+T细胞的细胞毒性,从而增加患糖尿病的风险。

2017-11-27 MedSci MedSci原创

人类1型糖尿病好发于青少年,由于胰腺β细胞受损,导致胰岛素缺乏,由于其是由遗传、免疫系统以及环境的复杂的相互作用所导致,所以到目前为止,其病理机制过程尚未完全清楚。现认为1型干扰素(T1-IFN)参与构成T1D患者胰腺内的自体炎症微环境。而IFNα/β在T1D患者胰腺中调控人类活化自体反应CR8+T细胞反应的能力尚未被研究过。现Brittney N.Newby等人构造人类β细胞特异性毒性T淋巴细胞

人类1型糖尿病好发于青少年,由于胰腺β细胞受损,导致胰岛素缺乏,由于其是由遗传、免疫系统以及环境的复杂的相互作用所导致,所以到目前为止,其病理机制过程尚未完全清楚。

现认为1型干扰素(T1-IFN)参与构成T1D患者胰腺内的自体炎症微环境。而IFNα/β在T1D患者胰腺中调控人类活化自体反应CR8+T细胞反应的能力尚未被研究过。

现Brittney N.Newby等人构造人类β细胞特异性毒性T淋巴细胞(CTL),T1-IFN可以浓度依赖性的方式诱导STAT4的快速磷酸化而激活,活化的STAT4直接结合于GZMB的启动子,上调GZMB的表达,从而增加CTL的毒性作用,进而导致β细胞溶解增加。

目前的研究结果提供了一种新的视角,即T1-IFN在人类抗原记忆CD8+T细胞中对效应功能的调控,并提出一种新的机制,即自身免疫性胰腺中的T1-IFN可增加人类患糖尿病的风险。

原始出处:

Brittney N.Newby,et al.Type 1 Interferons Potentiate Human CD8+ T-Cell Cytotoxicity Through a STAT4- and Granzyme B–Dependent Pathway.Diabetes 2017 Dec; 66(12): 3061-3071. https://doi.org/10.2337/db17-0106 .

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1760356, encodeId=d1701e60356f9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 29 17:48:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638209, encodeId=ae391638209de, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Dec 26 08:48:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794304, encodeId=9e201e9430461, content=<a href='/topic/show?id=e36516e561a' target=_blank style='color:#2F92EE;'>#STAT4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16756, encryptionId=e36516e561a, topicName=STAT4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Sat Jul 07 06:48:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784047, encodeId=c7321e840478b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Feb 13 22:48:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901861, encodeId=385e1901861ef, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Mar 17 07:48:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507504, encodeId=0859150e50409, content=<a href='/topic/show?id=2a25666db' target=_blank style='color:#2F92EE;'>#1型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=666, encryptionId=2a25666db, topicName=1型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6a9894431, createdName=bettycmoon, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529514, encodeId=a61515295143c, content=<a href='/topic/show?id=a02ce793707' target=_blank style='color:#2F92EE;'>#细胞毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77937, encryptionId=a02ce793707, topicName=细胞毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10b211951227, createdName=appleandpeer, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605373, encodeId=cab316053e334, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1760356, encodeId=d1701e60356f9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 29 17:48:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638209, encodeId=ae391638209de, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Dec 26 08:48:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794304, encodeId=9e201e9430461, content=<a href='/topic/show?id=e36516e561a' target=_blank style='color:#2F92EE;'>#STAT4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16756, encryptionId=e36516e561a, topicName=STAT4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Sat Jul 07 06:48:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784047, encodeId=c7321e840478b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Feb 13 22:48:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901861, encodeId=385e1901861ef, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Mar 17 07:48:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507504, encodeId=0859150e50409, content=<a href='/topic/show?id=2a25666db' target=_blank style='color:#2F92EE;'>#1型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=666, encryptionId=2a25666db, topicName=1型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6a9894431, createdName=bettycmoon, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529514, encodeId=a61515295143c, content=<a href='/topic/show?id=a02ce793707' target=_blank style='color:#2F92EE;'>#细胞毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77937, encryptionId=a02ce793707, topicName=细胞毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10b211951227, createdName=appleandpeer, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605373, encodeId=cab316053e334, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1760356, encodeId=d1701e60356f9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 29 17:48:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638209, encodeId=ae391638209de, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Dec 26 08:48:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794304, encodeId=9e201e9430461, content=<a href='/topic/show?id=e36516e561a' target=_blank style='color:#2F92EE;'>#STAT4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16756, encryptionId=e36516e561a, topicName=STAT4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Sat Jul 07 06:48:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784047, encodeId=c7321e840478b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Feb 13 22:48:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901861, encodeId=385e1901861ef, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Mar 17 07:48:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507504, encodeId=0859150e50409, content=<a href='/topic/show?id=2a25666db' target=_blank style='color:#2F92EE;'>#1型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=666, encryptionId=2a25666db, topicName=1型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6a9894431, createdName=bettycmoon, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529514, encodeId=a61515295143c, content=<a href='/topic/show?id=a02ce793707' target=_blank style='color:#2F92EE;'>#细胞毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77937, encryptionId=a02ce793707, topicName=细胞毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10b211951227, createdName=appleandpeer, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605373, encodeId=cab316053e334, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
    2018-07-07 zhu_jun9837
  4. [GetPortalCommentsPageByObjectIdResponse(id=1760356, encodeId=d1701e60356f9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 29 17:48:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638209, encodeId=ae391638209de, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Dec 26 08:48:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794304, encodeId=9e201e9430461, content=<a href='/topic/show?id=e36516e561a' target=_blank style='color:#2F92EE;'>#STAT4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16756, encryptionId=e36516e561a, topicName=STAT4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Sat Jul 07 06:48:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784047, encodeId=c7321e840478b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Feb 13 22:48:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901861, encodeId=385e1901861ef, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Mar 17 07:48:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507504, encodeId=0859150e50409, content=<a href='/topic/show?id=2a25666db' target=_blank style='color:#2F92EE;'>#1型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=666, encryptionId=2a25666db, topicName=1型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6a9894431, createdName=bettycmoon, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529514, encodeId=a61515295143c, content=<a href='/topic/show?id=a02ce793707' target=_blank style='color:#2F92EE;'>#细胞毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77937, encryptionId=a02ce793707, topicName=细胞毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10b211951227, createdName=appleandpeer, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605373, encodeId=cab316053e334, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
    2018-02-13 gds2009
  5. [GetPortalCommentsPageByObjectIdResponse(id=1760356, encodeId=d1701e60356f9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 29 17:48:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638209, encodeId=ae391638209de, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Dec 26 08:48:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794304, encodeId=9e201e9430461, content=<a href='/topic/show?id=e36516e561a' target=_blank style='color:#2F92EE;'>#STAT4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16756, encryptionId=e36516e561a, topicName=STAT4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Sat Jul 07 06:48:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784047, encodeId=c7321e840478b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Feb 13 22:48:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901861, encodeId=385e1901861ef, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Mar 17 07:48:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507504, encodeId=0859150e50409, content=<a href='/topic/show?id=2a25666db' target=_blank style='color:#2F92EE;'>#1型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=666, encryptionId=2a25666db, topicName=1型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6a9894431, createdName=bettycmoon, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529514, encodeId=a61515295143c, content=<a href='/topic/show?id=a02ce793707' target=_blank style='color:#2F92EE;'>#细胞毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77937, encryptionId=a02ce793707, topicName=细胞毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10b211951227, createdName=appleandpeer, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605373, encodeId=cab316053e334, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1760356, encodeId=d1701e60356f9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 29 17:48:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638209, encodeId=ae391638209de, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Dec 26 08:48:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794304, encodeId=9e201e9430461, content=<a href='/topic/show?id=e36516e561a' target=_blank style='color:#2F92EE;'>#STAT4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16756, encryptionId=e36516e561a, topicName=STAT4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Sat Jul 07 06:48:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784047, encodeId=c7321e840478b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Feb 13 22:48:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901861, encodeId=385e1901861ef, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Mar 17 07:48:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507504, encodeId=0859150e50409, content=<a href='/topic/show?id=2a25666db' target=_blank style='color:#2F92EE;'>#1型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=666, encryptionId=2a25666db, topicName=1型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6a9894431, createdName=bettycmoon, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529514, encodeId=a61515295143c, content=<a href='/topic/show?id=a02ce793707' target=_blank style='color:#2F92EE;'>#细胞毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77937, encryptionId=a02ce793707, topicName=细胞毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10b211951227, createdName=appleandpeer, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605373, encodeId=cab316053e334, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1760356, encodeId=d1701e60356f9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 29 17:48:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638209, encodeId=ae391638209de, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Dec 26 08:48:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794304, encodeId=9e201e9430461, content=<a href='/topic/show?id=e36516e561a' target=_blank style='color:#2F92EE;'>#STAT4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16756, encryptionId=e36516e561a, topicName=STAT4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Sat Jul 07 06:48:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784047, encodeId=c7321e840478b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Feb 13 22:48:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901861, encodeId=385e1901861ef, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Mar 17 07:48:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507504, encodeId=0859150e50409, content=<a href='/topic/show?id=2a25666db' target=_blank style='color:#2F92EE;'>#1型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=666, encryptionId=2a25666db, topicName=1型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6a9894431, createdName=bettycmoon, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529514, encodeId=a61515295143c, content=<a href='/topic/show?id=a02ce793707' target=_blank style='color:#2F92EE;'>#细胞毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77937, encryptionId=a02ce793707, topicName=细胞毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10b211951227, createdName=appleandpeer, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605373, encodeId=cab316053e334, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1760356, encodeId=d1701e60356f9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue May 29 17:48:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638209, encodeId=ae391638209de, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Dec 26 08:48:00 CST 2017, time=2017-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794304, encodeId=9e201e9430461, content=<a href='/topic/show?id=e36516e561a' target=_blank style='color:#2F92EE;'>#STAT4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16756, encryptionId=e36516e561a, topicName=STAT4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Sat Jul 07 06:48:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784047, encodeId=c7321e840478b, content=<a href='/topic/show?id=4b5c564252' target=_blank style='color:#2F92EE;'>#D8+T#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5642, encryptionId=4b5c564252, topicName=D8+T)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Tue Feb 13 22:48:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901861, encodeId=385e1901861ef, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Mar 17 07:48:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507504, encodeId=0859150e50409, content=<a href='/topic/show?id=2a25666db' target=_blank style='color:#2F92EE;'>#1型干扰素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=666, encryptionId=2a25666db, topicName=1型干扰素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f6a9894431, createdName=bettycmoon, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529514, encodeId=a61515295143c, content=<a href='/topic/show?id=a02ce793707' target=_blank style='color:#2F92EE;'>#细胞毒性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77937, encryptionId=a02ce793707, topicName=细胞毒性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10b211951227, createdName=appleandpeer, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605373, encodeId=cab316053e334, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Nov 29 13:48:00 CST 2017, time=2017-11-29, status=1, ipAttribution=)]

相关资讯

Nature:I型干扰素激活小胶质细胞导致中枢神经系统狼疮的机制

这项研究对于正在进行的I型干扰素受体拮抗剂anifrolumab7的临床试验评估有一定的支持意义,表现其有可能在治疗中枢神经狼疮有一定的作用。此外,这项研究还揭示了干扰素所驱动的小神经胶质细胞激活所导致的突触损失,并发布了这些病变的小胶质细胞的基因转录组数据,为进一步研究中枢系统神经狼疮与其他中枢神经疾病提供了一些基因层面的解释。

JEM:中科院巴斯德所肖晖研究组等发表pDC抗病毒感染研究成果

近日,国际免疫学领域重要的顶级期刊、洛克菲勒大学出版社的旗舰杂志《Journal of Experimental Medicine》在线发表了中科院上海巴斯德研究所肖晖研究组的最新研究成果:“Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDC

J Immunology:I型干扰素调控系统性硬化疾病发生

系统性硬化(systemic sclerosis)是一类复杂的自身免疫疾病,该疾病可以大致分为两类:一类是局部皮肤的硬皮病(limited cutaneous scleroderma),主要是患者的皮肤出现纤维化症状,同时伴随有"雷诺现象"以及肺脏血压升高;另一类是扩散性系统硬化,即患者多处组织器官发生病变。目前对造成该疾病的免疫系统紊乱的机制了解并不清楚,不过最近一些研究发现I型干扰素在多种自体

J Immunol:孙兵等发现负性调控I型干扰素产生的新分子NMI

8月16日,国际学术期刊Journal of Immunology在线发表了中国科学院上海生物化学与细胞生物学研究所孙兵研究组题为“Negative Regulation of Nmi on Virus-Triggered Type I IFN Production by Targeting IRF7”的研究论文。报道了病毒诱导的分子NMI(N-Myc and STATs interactor)可

Cancer Cell:I型干扰素靶向治疗抗体耐药肿瘤研究上的重大成果

2014年1月,中国科学院生物物理所傅阳心课题组在Cancer Cell杂志发表标题为“Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses”的论文。 该论文首度提出IFNβ靶向肿瘤治疗的新策略,即重建肿瘤微环境固有免疫和获得性免疫的协同作用、消除顽固耐

Cell:曹雪涛组报道抗病毒免疫新机制附专家点评:

I型干扰素是目前临床用于治疗慢性乙型肝炎的常用药之一,然而其总体有效率较低,治疗效果亟待提高。因此,全面深入认识干扰素抗病毒效应的具体机制以寻找有效防治病毒感染的免疫措施具有重要意义。7月27日,曹雪涛院士研究团队在Cell杂志上发表了题为“Methyltransferase SETD2-Mediated Methylation of STAT1 Is Critical for Interfero